Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis

(2018) Giovanni Caocci et al.   ACTA HAEMATOLOGICA

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018

(2017) Ruben A. Mesa et al.   Journal of the National Comprehensive Cancer Network

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis

(2016) Veronika Buxhofer-Ausch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

(2016) H. K. Al-Ali et al.   HAEMATOLOGICA

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

(2016) H. K. Al-Ali et al.   HAEMATOLOGICA

Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms

(2015) N. Polverelli et al.   ANNALS OF HEMATOLOGY

Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

(2015) Jiří Schwarz et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

(2015) A. M. Vannucchi et al.   HAEMATOLOGICA

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

(2015) A. M. Vannucchi et al.   HAEMATOLOGICA

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

(2013) A. Tefferi et al.   BLOOD

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

(2012) Robyn M. Emanuel et al.   JOURNAL OF CLINICAL ONCOLOGY

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

(2012) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management

(2011) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

(2010) Alejandra Martínez-Trillos et al.   ANNALS OF HEMATOLOGY

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*

(2010) Eva Löfvenberg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera

(2009) Naseema Gangat et al.   CANCER

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

(2008) A. Carobbio et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD